XML 45 R30.htm IDEA: XBRL DOCUMENT
v3.8.0.1

License and Collaboration Agreements - Additional Information (Detail) - USD ($) |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Aug. 23, 2017 | Sep. 21, 2016 | May 30, 2016 | Mar. 01, 2016 | Sep. 16, 2014 | Jan. 31, 2017 | Aug. 31, 2016 | Mar. 31, 2016 | Nov. 30, 2015 | Jun. 30, 2014 | Jun. 30, 2013 | Feb. 29, 2012 | Sep. 30, 2017 | Dec. 31, 2010 | Dec. 31, 2009 | Sep. 30, 2017 | Sep. 30, 2016 | Dec. 31, 2013 | Dec. 31, 2007 | Dec. 31, 2017 | Dec. 31, 2016
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential future additional payments for development milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 397,000,000 |  |  |  |  |
Liability for refundable upfront payment |  |  |  |  |  |  |  |  |  |  |  |  | $ 12,500,000 |  |  | 12,500,000 |  |  |  |  | $ 12,500,000
AstraZeneca-Kirin [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments |  |  |  | 40.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ONZEALDTM (NKTR-102) [Member] | Turkey [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of royalty on net sales |  |  | 15.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nektar's [Member] | NKTR-358 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of sharing in Phase 2 development costs | 25.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Eli Lilly and Company [Member] | NKTR-358 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 150,000,000 |  |  |  |  |
Percentage of sharing in Phase 2 development costs | 75.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of regulatory milestones payments will be reduced under certain conditions | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of regulatory milestones payments will be reduced if conditions occur | 75.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Regulatory milestones payment, description |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | A portion of these regulatory milestones may be reduced by 50% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by 75% if both conditions occur. |  |  |  |  |
Revenue related to Phase 1 clinical development and drug development activities |  |  |  |  |  |  |  |  |  |  |  |  | 1,700,000 |  |  |  |  |  |  |  |
Eli Lilly and Company [Member] | NKTR-358 [Member] | License [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 125,900,000 |  |  |  |  |
Revenue related to license and product development activities |  |  |  |  |  |  |  |  |  |  |  |  | 125,900,000 |  |  |  |  |  |  |  |
Eli Lilly and Company [Member] | NKTR-358 [Member] | Phase 1 Clinical Development [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 17,600,000 |  |  |  |  |
Eli Lilly and Company [Member] | NKTR-358 [Member] | Drug Product Development [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,500,000 |  |  |  |  |
Eli Lilly and Company [Member] | NKTR-358 [Member] | Phase 1 Clinical Development and Drug Product Development [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  | 22,400,000 |  |  | 22,400,000 |  |  |  |  |
Eli Lilly and Company [Member] | NKTR-358 [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential future additional development and regulatory milestones | $ 250,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Indication by indication basis phase 3 percent of development costs | 25.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Eli Lilly and Company [Member] | NKTR-358 [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Indication by indication basis phase 3 percent of development costs | 0.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AstraZeneca AB [Member] | MOVANTIK and MOVANTIK fixed-dose combination program [Member] | Upfront Payment Arrangement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 125,000,000 |  |  |  |  |  |
AstraZeneca AB [Member] | MOVANTIK Fixed-dose Combination Program [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential contingent payments based on development events |  |  |  |  |  |  |  |  |  |  |  |  | 75,000,000 |  |  | 75,000,000 |  |  |  |  |
AstraZeneca AB [Member] | AstraZeneca-Kirin [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  | $ 28,000,000 |  |  |  |  |  |  |  | 4,600,000 |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  |  |  |  |
Upfront and milestone payments received by Our collaboration partner under sublicense arrangement |  |  |  | $ 70,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments from sublicense agreement retained by our collaboration partner |  |  |  | 60.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AstraZeneca AB [Member] | MOVANTIK [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of post approval study costs to repay |  |  |  |  | 33.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum potential reduction in royalties |  |  |  |  | $ 35,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AstraZeneca AB [Member] | MOVANTIK [Member] | United States [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential reduction in U.S. royalty rate for repayment |  |  |  |  | 2.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amgen, Inc. [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 50,000,000 |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  | 15,400,000 |  |  | 15,400,000 |  |  |  |  |
Bayer Healthcare LLC [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential future additional payments for development milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50,000,000 |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  | 16,800,000 |  |  | 16,800,000 |  |  |  |  |
Payment made to Bayer for cost of Phase 3 clinical trial |  |  |  |  |  |  |  |  |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |
Potential future development milestones related to FDA approval |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 22,500,000 |  |  |  |  |
Bayer Healthcare LLC [Member] | Performance-based Milestone Payments [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 30,000,000 |  |  |
Bayer Healthcare LLC [Member] | Upfront Payment Arrangement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 40,000,000 |  |
Daiichi Sankyo Europe GmbH [Member] | ONZEALDTM (NKTR-102) [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Eligible milestone payments receivable upon achievement of regulatory and commercial milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 60,000,000 |  |  |  |  |
Milestone payments to be received upon first commercial sales |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10,000,000 |  |  |  |  |
Milestone payment to be received upon first commercial sale after final regulatory approval |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 25,000,000 |  |  |  |  |
Milestone payment to be received upon first achievement of annual net sales target |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 25,000,000 |  |  |  |  |
Liability for refundable upfront payment |  |  |  |  |  |  |  |  |  |  |  |  | 12,500,000 |  |  | 12,500,000 |  |  |  |  | $ 12,500,000
Daiichi Sankyo Europe GmbH [Member] | ONZEALDTM (NKTR-102) [Member] | European Territory Except Turkey [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of royalty on net sales |  |  | 20.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Daiichi Sankyo Europe GmbH [Member] | ONZEALDTM (NKTR-102) [Member] | Upfront Payment Arrangement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  | $ 20,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  | 3,200,000 |  |  | 3,200,000 |  |  |  |  |
Non-refundable portion of upfront payment |  |  | $ 7,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable portion of upfront payment, subject to conditional marketing approval |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 12,500,000 |  |  |  |  |
Revenue recognized from upfront payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,500,000 |  |  |  |
Daiichi Sankyo Europe GmbH [Member] | ONZEALDTM (NKTR-102) [Member] | Development Service Obligation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized from upfront payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 600,000 |  |  |  |  |
Baxalta Incorporated [Member] | ADYNOVATE (Hemophilia) [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  |  |  |  |
Development milestones achieved |  |  |  |  |  |  |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Baxalta Incorporated [Member] | ADYNOVATE (Hemophilia) [Member] | European Union [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential future additional payments for development milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10,000,000 |  |  |  |  |
Roche [Member] | MIRCERA [Member] | Performance-based Milestone Payments [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  |  |  |  |  | $ 22,000,000 |  |  |  |  |  |  |  |  |
Roche [Member] | MIRCERA [Member] | Upfront Payment Arrangement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  |  |  |  |  | $ 5,000,000 |  |  |  |  |  |  |  |  |
Ophthotech Corporation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Advances from collaboration partner payment |  |  |  |  |  | $ 12,700,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ophthotech Corporation [Member] | Reagent Shipments [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Advances from collaboration partner payment |  |  |  |  |  | 10,400,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ophthotech Corporation [Member] | Minimum Purchase Requirement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Advances from collaboration partner payment |  |  |  |  |  | $ 2,300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ophthotech Corporation [Member] | Fovista [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  | 18,000,000 |  |  | $ 18,000,000 |  |  |  |  |
Ophthotech Corporation [Member] | Fovista [Member] | Novartis Pharma AG [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  |  |  | $ 19,800,000 |  |  |  |  |  |  |  |  |  |  |
Ophthotech Corporation [Member] | Fovista [Member] | Scenario, Forecast [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 18,000,000 |
Bristol-Myers Squibb [Member] | NKTR-214 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of out-of-pocket costs to be reimbursed by partner |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement exclusivity expiration date |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Sep. 30, 2018 |  |  |  |  |
License agreement exclusivity negotiation period |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 months |  |  |  |  |
Other [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential future additional payments for development milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 45,500,000 |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,900,000 |  |  | $ 5,900,000 |  |  |  |  |

X
- Definition Advance payment received from collaboration partner. + References No definition available. + Details
Name: | nktr_AdvancePaymentReceivedFromCollaborationPartner
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Eligible milestone payments receivable upon achievement of regulatory and commercial milestones. + References No definition available. + Details
Name: | nktr_EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndCommercialMilestones
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Indication by indication basis phase 3 percent of development costs. + References No definition available. + Details
Name: | nktr_IndicationByIndicationBasisPhaseThreePercentOfDevelopmentCosts
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Liability for refundable upfront payment. + References No definition available. + Details
Name: | nktr_LiabilityForRefundableUpfrontPayment
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition License agreement exclusivity expiration date. + References No definition available. + Details
Name: | nktr_LicenseAgreementExclusivityExpirationDate
Namespace Prefix: | nktr_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition License agreement exclusivity negotiation period. + References No definition available. + Details
Name: | nktr_LicenseAgreementExclusivityNegotiationPeriod
Namespace Prefix: | nktr_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone payment to be received upon first achievement of annual net sales target. + References No definition available. + Details
Name: | nktr_MilestonePaymentToBeReceivedUponFirstAchievementOfAnnualNetSalesTarget
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payment to be received upon first commercial sale after final regulatory approval. + References No definition available. + Details
Name: | nktr_MilestonePaymentToBeReceivedUponFirstCommercialSaleAfterFinalRegulatoryApproval
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments to be received upon first commercial sales. + References No definition available. + Details
Name: | nktr_MilestonePaymentsToBeReceivedUponFirstCommercialSales
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Non-refundable portion of upfront payment. + References No definition available. + Details
Name: | nktr_NonRefundablePortionOfUpfrontPayment
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Non refundable portion of upfront payment subject to conditional marketing approval. + References No definition available. + Details
Name: | nktr_NonRefundablePortionOfUpfrontPaymentSubjectToConditionalMarketingApproval
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payment made to Bayer for reimbursement cost of Phase 3 clinical trial. + References No definition available. + Details
Name: | nktr_PaymentForReimbursementOfCosts
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of out of pocket costs to be reimbursed by partner. + References No definition available. + Details
Name: | nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of post approval study costs to repay. + References No definition available. + Details
Name: | nktr_PercentageOfPostApprovalStudyCostsToRepay
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalty on net sales. + References No definition available. + Details
Name: | nktr_PercentageOfRoyaltyOnNetSales
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of sharing in Phase 2 development costs. + References No definition available. + Details
Name: | nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments. + References No definition available. + Details
Name: | nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of upfront payment market access milestone payments royalties and sales milestone payments from sublicense agreement retained by our collaboration partner. + References No definition available. + Details
Name: | nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential contingent payments based on development events. + References No definition available. + Details
Name: | nktr_PotentialContingentPaymentsBasedOnDevelopmentEvents
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Potential development and regulatory milestones. + References No definition available. + Details
Name: | nktr_PotentialDevelopmentAndRegulatoryMilestones
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Potential development milestones. + References No definition available. + Details
Name: | nktr_PotentialDevelopmentMilestones
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Potential development milestones related to regulatory approval. + References No definition available. + Details
Name: | nktr_PotentialDevelopmentMilestonesRelatedToRegulatoryApproval
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Potential reduction in future royalty payments to repay post approval studies. + References No definition available. + Details
Name: | nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | instant

X
- Definition Potential royalty reduction on sales to repay post-approval study if required. + References No definition available. + Details
Name: | nktr_PotentialRoyaltyReductionOnSalesToRepayPostApprovalStudyIfRequired
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Regulatory milestones payment, description. + References No definition available. + Details
Name: | nktr_RegualtoryMilestonesPaymentDescription
Namespace Prefix: | nktr_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Regulatory milestones payment reduction percentage upon conditions occur. + References No definition available. + Details
Name: | nktr_RegulatoryMilestonesPaymentReductionPercentageUponConditionsOccur
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Regulatory milestones payments reduction percentgae under conidtions. + References No definition available. + Details
Name: | nktr_RegulatoryMilestonesPaymentsReductionPercentgaeUnderConidtions
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue recognized from upfront payment. + References No definition available. + Details
Name: | nktr_RevenueRecognizedFromUpfrontPayment
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue requiring delivery of multiple elements. + References No definition available. + Details
Name: | nktr_RevenueRequiringDeliveryOfMultipleElements
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront and milestone payments received by our collaboration partner under sublicense arrangement. + References No definition available. + Details
Name: | nktr_UpfrontAndMilestonePaymentsReceivedByOurCollaborationPartnerUnderSublicenseArrangement
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront and milestone payments received under license agreement. + References No definition available. + Details
Name: | nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DeferredRevenueArrangementLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue from multiple-deliverable arrangements that include licensing fees and maintenance revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Maintenance revenue is derived from maintenance services provided under contracts or arrangements with clients. Services may include the maintenance of software, plant and equipment, and facilities. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(d),(e)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_LicenseAndMaintenanceRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_AstraZenecaAgreementWithKirinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_ONZEALDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_TR
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidatedEntitiesAxis=us-gaap_ParentCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_NektarThreeFiveEightMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=nktr_LicenseArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=nktr_PhaseOneClinicalDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=nktr_DrugProductDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=nktr_PhaseOneClinicalDevelopmentAndDrugProductDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_AstraZenecaAbMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_MOVANTIKAndMOVANTIKFixedDoseCombinationProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_MOVANTIKFixedDoseCombinationProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_MOVANTIKMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_AmgenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_BayerHealthcareLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis=nktr_PerformanceMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_DaiichiSankyoEuropeGmbHMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=nktr_EuropeanTerritoryExceptTurkeyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=nktr_DevelopmentServiceObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_BaxaltaIncorporatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_HemophiliaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=us-gaap_EuropeanUnionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_RocheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_MIRCERAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_OphthotechCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=nktr_ReagentShipmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=nktr_MinimumPurchaseRequirementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_FovistaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nktr_NovartisPharmaAgMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_NektarTwoOneFourMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_OtherPartnerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |